In the last decade, the world has witnessed notable developments in cardiac monitoring devices, offering physicians and patients new approaches to manage many diseases, including atrial arrhythmias, ventricular arrhythmias, and ventricular atrial fibrillation. The growing prevalence of cardiovascular diseases (CVDs) such as coronary heart diseases, sudden cardiac arrest, congenital heart diseases, heart failure, pulmonary hypertension, and pulmonary artery pressure (PA) is encouraging the introduction of improved monitoring methods. The simplicity of use and the ability to detect cardiovascular diseases (CVDs) quickly are the factors adding to the popularity of cardiac monitoring devices. The European Society of Cardiology reported that atrial fibrillation is the most common arrhythmia, and it accounts for 0.28–2.6% of healthcare spending in European countries. It also mentioned that patients suffering from atrial fibrillation are at a five-time greater risk of getting a stroke, and 20–30% of total stroke cases in Europe are caused due to atrial fibrillation. As per a study conducted by the European Society of Cardiology in 2016, ~7.6 million people of age 65 and above had atrial fibrillation in the EU, and the number is estimated to increase by 89% to reach ~14.4 million by 2060. The prevalence of atrial fibrillation is estimated to reach 9.5% by 2060 from 7.8% in 2016. A few of the primary risk factors of CVDs include family history, ethnicity, and age; other risk factors include tobacco consumption, hypertension, obesity, high cholesterol, physical inactivity, diabetes, unhealthy diets, and alcohol consumption. Further, lifestyle changes lead to the rise in the incidence of diabetes, hypertension, dyslipidemia, and obesity, contributing to a surge in CVD cases across the world. Most CVD cases can be prevented through proactive monitoring and early diagnosis, which bolsters the need for cardiac monitoring devices.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe cardiac monitoring devices market in the coming years. The market is expected to grow at a good CAGR during the forecast period.
The Europe cardiac monitoring devices market is segmented on the basis of type, product type, application, end user, and country. Based on type, the market is segmented into cardiovascular devices, multi-parameter ECG monitors, patient monitoring devices, ambulatory cardiac monitoring, and cardiac monitors. In 2020, the cardiovascular devices segment held the largest share of the market. Based on product type, the Europe cardiac monitoring devices market is segmented into portable monitor, smart wearable monitor, and standard monitor. In 2020, the standard monitor segment held the largest share of the market. Based on application, the market is segmented into coronary heart diseases, sudden cardiac arrest, stroke, arrhythmia, congenital heart diseases, heart failure, pulmonary hypertension, heart function (HF/LVEDP), pulmonary artery pressure (PA), and others. The coronary heart diseases segment held the largest market share in 2020 and is expected to be the largest shareholder in the market by 2028. Based on end user, the Europe cardiac monitoring devices market is segmented into hospitals, ambulatory surgery centers (ASCs), and clinics. The hospitals segment held the largest market share in 2020. Based on country, the Europe cardiac monitoring devices market is segmented into France, Germany, Italy, Spain, the UK, and the rest of Europe. Abbott; Amiitalia; Asahi Kasei Corporation; Bionet America, Inc.; Biotronik, Inc.; Boston Scientific Corporation; BTL; GE Healthcare; Hill-Rom Holdings, Inc.; Infinium Medical; iRhythm Technologies, Inc.; Koninklijke Philips N.V.; LivaNova PLC; Medtronic; MicroPort Scientific Corporation; Mortara Instruments; Nihon Kohden Corporation; SCHILLER Healthcare India Pvt. Ltd; and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. are among the leading companies in the market.